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Coagulation factor V circulates in plasma as a single chain protein which expresses little procoagulant 
activity. After its activation by limited proteolysis by thrombin or factor Xa, factor Va functions as 
cofactor to factor Xa in the activation of prothrombin. Thrombin cleaves human factor V at Arg709, 
Argl018 and Argl545 and factor Va is formed by the heavy and light chains, which correspond to the 
N-terminal and C-terminal fragments, respectively. Factor Xa has been shown to cleave factor V at 
Argl018 and at a second undefined position close to Arg709. The factor-Xa-mediated cleavage at 
Argl018 has been proposed to be sufficient for expression of full factor Va activity. To study the activation 
of factor V by factor Xa, site-directed mutagenesis was used to convert Arg709 to Gln, Argl018 to Ile, 
and Arg1545 to Gln. Constructs containing all possible combinations of native and mutated residues in 
these positions were expressed transiently in COS 1 cells. The various factor-\/ mutants were incubated 
with factor Xa or thrombin. The proteolytic cleavage pattern was analyzed by Western blotting, and the 
specific factor-Va activities determined in a prothrombinase assay. Control experiments using thrombin 
gave results which were in agreement with those on record, i.e. cleavages at both Arg709 and Arg1545 
were required for expression of full factor-Va activity, whereas the cleavage at Argl018 enhanced the 
rate of cleavage at Arg1545. Factor Xa was found to cleave factor V at all three thrombin cleavage sites, 
i.e. at Arg709, Argl018 and Arg1545. An additional factor-Xa-cleavage site was found in the light chain 
region at Arg1765. Cleavage at Argl018 by factor Xa was not sufficient for expression of full factor-Va 
activity. Full factor-Va activity was only obtained after cleavage at both Arg709 and Arg1545. The factor- 
Xa-mediated cleavage at Arg709 was kinetically favourable over that at Arg1545. Factor V which was 
mutated at all three sites (at positions 709, 1018 and 1545) was resistant to activation by thrombin. 
However, treatment with factor Xa yielded an increased factor-Va activity which was associated with the 
cleavage at Arg1765. Our study extends previously results on thrombin activation of factor V and eluci- 
dates the relative importance of the different cleavage sites for activation of factor V by factor Xa. 
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Coagulation factor V is a single chain glycoprotein ( M ,  
330000) circulating in human plasma at a concentration of 7- 
10 mg/ml (reviewed in 11, 21). Like the homologous factor VIII 
molecule, factor V is composed of multiple A and C domains 
and a single B region (schematic model of factor V is shown in 
Fig. 4). Factor Va plays an important role as a phospholipid- 
bound cofactor to factor Xa in the activation of prothrombin. 
However, intact single chain factor V has little procoagulant ac- 
tivity and it is only after limited proteolysis by thrombin or 
factor Xa that factor V expresses full factor-Xa cofactor activity 
P I .  
Activation of factor V by thrombin is the result of three 
proteolytic cleavages. at Arg709, ArglOl8 and Argl545 141. The 
activation process is associated with a major molecular re- 
arrangement and only 50% of the factor-V mass forms the active 
species. Thus, factor Va is composed of the 105-kDa heavy 
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chain (A1 and A2 domains) and the 71/74-kDa light chain (A3, 
C1 and C2 domains), which are derived from the N-terminal 
and C-terminal parts, respectively of factor V. The two chains of 
factor Va are held together by non-covalent calcium-dependent 
bonds. The B region is released from factor Va as two activation 
fragments of 71 kDa and 150 kDa [5-71. 
Factor Xa is the enzyme that cleaves and activates prothroni- 
bin, and factor Va serves to enhance the catalytic efficiency of 
the factor-Xa-mediated cleavage [ 1, 21. The light chain of factor 
Va binds the phospholipid membrane 18- 1 I], whereas the heavy 
chain interacts with prothrombin [12]. Once factor Va is bound 
to the membrane, both the heavy and the light chains contribute 
to the binding of factor Xa [13]. Factor Va lacking the heavy- 
chain region Asp683-Arg709 has reduced factor Xa cofactor 
activity and demonstrates impaired binding of factor Xa and 
prothrombin, suggesting that the C-terminal part of the heavy 
chain is required for optimal interaction with factor Xa and 
prothrombin 1241. 
To elucidate the relative importance of the three thrombin- 
cleavage sites, Keller and coworkers [ 151 replaced the arginine 
residues at these sites with isoleucine residues and concluded 
that cleavage at Arg1.545 was crucial for maximal activation of 
factor V. This is consistent with the finding that a factor-V acti- 
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vator isolated from Russell’s viper venom (RVV) cleaves factor 
V at Arg1545, which leads to expression of full factor-Va activ- 
ity [ I ,  15, 161. 
The molecular events occurring upon activation of factor V 
by factor Xa which lead to increased expression of factor-Va 
procoagulant activity, are still incompletely understood. Mon- 
covic and Tracy [I 7) demonstrated by N-terminal sequencing 
that factor Xa cleaves human plasma-derived factor V after Arg 
1018, and proposed that factor Xa cleaved at a site adjacent to 
or at Arg709. These authors did not detect factor-Xa-mediated 
formation of the light chain and they suggested that cleavage at 
ArglOl8 was sufficient to fully activate factor V. In contrast to 
results obtained with plasma-derived factor V, the light chain 
was found to be formed upon activation of platelet factor V by 
factor Xa [18]. Moreover, plasma-derived bovine factor V has 
been shown to be cleaved by factor Xa at two sites in the light 
chain region, giving rise to light chain fragments of 30 kDa and 
46/48 kDa [ 191. 
This site-directed mutagenesis study was performed to eluci- 
date which sites in human factor V are cleaved by factor Xa and 
to investigate the relative importance of the three cleavage sites, 
Arg709, ArglOl8 and Arg1545 for activation by factor Xa. The 
activation of the factor-V mutants by thrombin was studied in 
parallel for comparison and as a positive control. Factor Xa was 
found to cleave at the same three sites as thrombin and, in addi- 
tion, at a site within the light chain, the latter cleavage being 
sufficient for partial activation of factor V. In contrast to previ- 
ous reports, our results show that the factor Xa cleavage at 
Arg1545 was necessary for full activation of factor V. 
EXPERIMENTAL PROCEDURES 
Reagents. Restriction enzymes, PWO polymerase and T4 
DNA ligase were purchased from Boehringer Mannheim. 
Double-stranded DNA sequencing kit was from Perkin Elmer. 
Cell culture media (Optimem, glutamax) were from Gibco, 
BRL. An amplification kit for development of Western-blot 
membranes with fluorescence was from Amersham. The molec- 
ular-mass standards were from Bio-Rad. Phospholipid vesicles 
composed of 25 % (by mass) L-a-phosphatidyl-L-serine (P7769 
from bovine brain; Sigma), 37.5% (by mass) L-a-phosphati- 
dylcholine (P5763 from egg yolk; Sigma) and 37.5 % (by mass) 
L-a-phosphatidylethanolamine (P7693 from bovine brain; 
Sigma) were prepared as described previously [20]. The chro- 
mogenic substrate S-2238 was obtained from Chromogenix. 
Rabbit polyclonal anti-human factor V serum (A299) and rabbit 
anti-sheep IgG coupled to horse radish peroxidase were 
purchased from Dakopatts. A rabbit polyclonal anti-human 
factor Va light chain serum (8138) was raised as described pre- 
viously [21]. Sheep anti-human factor V polyclonal serum were 
from binding site. 
Proteins. The factor V activator from RVV was purified as 
described [22]. Human thrombin and factor Xa were purchased 
from Haematologic Technologies Inc. Human factor V was puri- 
fied as described previously [7, 231 and human prothrombin as 
described by Stenflo [24]. 
Mutagenesis. The Argl018 to Ile mutation has been pre- 
viously described [25]. At positions 709 and 1545 we chose to 
make the more conservative replacement of Arg to Gln. The 
mutations were created by PCR using an expression vector 
containing the full length cDNA of human factor V, PMT2-V 
[26] as template. For construction of the Arg 709 to Gln muta- 
tion, oligonucleotides S’GCATTAGGAATTCAATCATTCCG- 
AAAC-3‘ (1 ; nucleotides 2287 -23 13) and 5’-GTTTTAAGAG- 
TAACAGATCACTAG-3’ (2 ; nucleotides 2896-2873) were 
used in the first PCR. The second PCR used oligonucleotides 
S’-GTTTCGGAATGATTGAATTCCTAATGC-3‘ (3; nucleo- 
tides 23 13 - 2287) and S’-GTGTTTGATGAGAACAAAAGC-3’ 
(4; nucleotides 1738-1758). In the third PCR, the products 
from PCR reactions 1 and 2 were used as templates together 
with oligonucleotides 2 and 4. The 900-bp PCR fragment result- 
ing from the third PCR reaction was cut with BlpI and KpnI, 
then ligated to two other fragments, a 9-kb PMT2-V vector- 
containing fragment (PMT2-V cut with KpnI to yield a 9-kb 
fragment) and a 2.1-kb factor-V cDNA fragment (derived from 
PMT2-V when cut with BlpI and KpnI). Positive colonies con- 
taining full length factor V were sequenced to confirm the muta- 
tion. 
The Arg1545 to Gln mutation was done in one PCR reaction 
using PMT2-V as template and oligonucleotides 5’-GCATGGT- 
ACCTCCAAAGCAACAATGGA-3‘ ( 5  ; nucleotides 4797- 
4821) and 5’-CCCTGATCGCTCAGTGGCATG-3’ (6 ; nucleo- 
tides 5241 -5221). The resulting 400-bp PCR fragment was cut 
with SnaBI and KpnI and ligated to two other fragments, an 
8.6-kb PMT2-V vector-containing fragment (PMT2-V was cut 
with SnaBI and KpnI to yield the 8.6-kb fragment) and a 3.0-kb 
KpnI factor V cDNA fragment (derived from KpnI-cleaved 
PMT2-V). Positive colonies containing full length factor V were 
subjected to automatic DNA sequencing to confirm the muta- 
tion. Once the single mutants had been created, factor-V mutants 
containing all the possible combinations of mutations were con- 
structed using restriction enzyme digestions and ligations of ap- 
propriate fragments. The three single-site mutants were called 
[Gln709]factorV, [Ilel018]factorV and [Glnl545]factorV, the 
double mutants [Gln709,Ile1018]factorV, [Ile1018,GIn1545]- 
factorv, and [Gln709,Gln1545]factorV, and the triple mutant 
[Gln709,Ile1018,Gln1545]factorV. The wild-type recornbinant 
factor-V molecule contained arginine residues at the three posi- 
tions. 
Expression and quantification of recombinant factor V. 
The recombinant proteins were expressed in COS 1 cells as de- 
scribed previously [26] and the proteins were collected in a se- 
rum-free medium (Optimem Glutamax) 65 hours after transfec- 
tion. The expression level was determined with ELISA. Microti- 
ter wells were coated overnight at 4°C with 10 mg/ml polyclonal 
rabbit-anti human factor V serum (8138). The plates were 
quenched for 30 min with 50 mM Tris, 150 mM NaCI, 0.1 % 
(mass/vol.) BSA, pH 7.4 (TrislNaClIBSA), then washed three 
times with 0.1 % (by vol.) Tween-20 in TrislNaCI. Samples were 
added at different dilutions and, after 2 hours incubation, the 
plates were washed three times and polyclonal sheep anti-human 
factor V serum (PC 105) was added. After washing, bound PC 
105 was detected with a horseradish-peroxidase-coupled rabbit 
anti-sheep serum. The plates were developed for 10 min with 
1,2-phenylenediamine (Dakopatts) and H,O, diluted in 0.1 M 
sodium citrate, pH 5.0. The reaction was stopped by the addition 
of 1.0 M H,SO, and the absorbance measured at 490 nm. Stan- 
dard curves were constructed using purified plasma-derived hu- 
man factor V. Samples and antibodies were diluted in Tris/NaCl/ 
BSA. 
Thrombin-catalyzed and factor-Xa catalyzed activation 
of recombinant factor V. Recombinant factor V from condi- 
tioned media was diluted to 1.5 nM in TrisNaCUBSA and incu- 
bated for 30 min at 37°C with different concentrations of throm- 
bin (0-6.4nM) in the presence of CaC1, (2.0mM), or with 
factor Xa (0- 1.5 nM) in the presence of phospholipids (20 pM) 
and CaCl, (2.0 mM). To follow the time course of the reaction, 
the recombinant factor-V preparations, diluted to 1.5 nM in Tris/ 
NaCI/BSA, were incubated at 37°C with thrombin (3.2 nM) in 
the presence of CaC1, (2.0 mM) or with factor Xa (1.5 nM) in 
the presence of phospholipids (20 pM) and CaCI, (2.0 mM). At 
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different time points (0-30 min), samples were drawn and 
assayed for factor-Va activity. 
Factor-Va activity assay. Eppendorf tubes containing 97 pl 
of a mixture of prothrombin (1 .O pM), phospholipids (20 pM) 
and CaCI, (2.0 mM) in Tris/NaCI/BSA (mixture A) were pre- 
pared and kept on ice. Factor V/Va (1.5 pl drawn from the 
thrombin-catalyzed or factor-Xa-catalyzed activation mixtures} 
was added to mixture A to give a final concentration of 22.5 
pM. Immediately thereafter, the prothrombin activation was ini- 
tiated by the addition of factor Xa (1.5 p1 4.0 nM stock solution 
giving a final concentration of 60 pM) and the tubes were trans- 
ferred to 37°C. To measure thrombin generation, aliquots of the 
reaction mixtures were drawn after 5 min and diluted 1:s in a 
buffer (50 mM Tris, 150 mM NaCl, 10 mM EDTA, 0.1 % (mass/ 
vol.) poly(ethylene glycol)-6000, pH 7 . 3 ,  and stored on ice until 
all the samples were collected. 5-10 p1 of the solutions were 
added to microtiter wells containing 85-90 pl buffer ( S O  mM 
Tris, 150 mM NaCI, 20 mM EDTA, 1 % (mass/vol.) poly(ethy1- 
ene glycol)-6000, pH 7.9) and 5 pl 4.0 inM S-2238, warmed to 
37°C. After 10 min, the reactions were stopped by the addition 
of 60 pl glacial acetic acid and the absorbance was read at 
405 nm. When factor V was activated by factor Xa in the pres- 
ence of phospholipid, thrombin generation was linear with time 
after an initial short lag phase of approximately 30 s. When 
factor V was activated by thrombin, the rate of thrombin genera- 
tion gradually increased during the first l - l .5 rnin before the 
thrombin generation was linear with time. At low concentrations 
of factor Xa and factor Va, it is probable that establishment of 
the factor-Xa-factor-Va complex formation equilibrium may 
take some time. Possibly, in the experiments in which factor V 
is activated by factor Xa in the presence of phospholipid, this 
equilibrium was already established in the activation mixture, 
which resulted in faster initial thrombin generation. This may 
result in a slight overestimation of the specific activity after 
factor-Xa activation, as compared to thrombin activation. How- 
ever, this overestimation of factor-% activity was relatively 
small and the difference did not significantly affect the inter- 
pretation of the results. Samples without factor Va (blanks) did 
not show any activity in the prothrombinase assay. Standard 
curves were prepared using pooled barium-adsorbed (using 
BaC1,) human plasma. Diluted plasma was activated with the 
RVV factor-V activator (1.65 pg/ml) for 10 rnin at 37°C and 
assayed at different concentrations in the prothrombinase assay. 
The RVV factor-V activator was used rather than thrombin to 
activate plasma factor V because thrombin induced clotting of 
fibrinogen. One unit of factor Va was defined as the activity 
present in 1 ml fully activated human plasma. 
Western-blot analysis of factor-V activation by thrombin 
or Xa. Prior to activation, conditioned media was concentrated 
in a Centricon 30 concentrator (Amicon). Recombinant factor V 
(25-SOnM) was activated with thrombin (24 nM), or with 
factor Xa (factor V/factor Xa; 4: 1 and 1: 1 molar ratio) for 
10 min at 37°C in Tris/NaCl. When recombinants were activated 
with factor Xa, 2.0 mM CaCI, and SO pM phospholipids were 
added. Samples were reduced with dithiothreitol and heated at 
90°C for 5 min. The proteins were run on SDS/PAGE using 5-  
13 % gradients, then transferred to poly(viny1idene difluoride) 
membranes using a semidry transfer blotting technique. The pro- 
teins were detected using A299, a polyclonal antibody against 
human factor V. Two Western-blot developing techniques were 
used to visualize the protein bands. (A) An alkaline-phospha- 
tase-conjugated swine anti-rabbit serum was used as secondary 
antibody. After development of the bands, the membranes were 
scanned in a densitometer (Molecular Dynamics). (B) A second- 
ary antibody, swine anti-rabbit coupled to fluorescein was used 
from a Western blotting kit (Amersham). The membranes were 
scanned in a FluorImager (Molecular Dynamics) at 530 nm. 
When the intensity of the bands was low, the membranes were 
incubated with a third antibody, an alkaline-phosphatase-coupled 
anti-fluorescein antibody, and the signal was amplified by the 
addition of Attophos and the membranes were scanned at 
570 nm. 
N-terminal sequence analysis. Factor V purified from 
plasma was activated with factor Xa at a 1 : 1 molar ratio for 
20 rnin at 37°C in the presence of phospholipids and CaCI,. The 
proteins were run on reduced SDS/PAGE using 5 - 15 % gradient 
gels, then transfened to ProBlot membrane (Applied Biosys- 
terns). Following transfer, the membrane was stained with Coo- 
massie brilliant blue and the 46/48-kDa fragment derived from 
the C-terminal part of the light chain excised from the membrane 
and sequenced as described previously [27]. 
RESULTS 
Expression and characterization of recombinant factor V. In 
order to study the activation of factor V by thrombin and factor 
Xa, site-directed niutagenesis and eukaryotic expression was 
used to prepare recombinant factor V having either arginine or 
glutamine residues at positions 709 and/or 1545, and arginine or 
isoleucine residues at position 1018. Wild-type factor V and 
seven mutants containing one, two or three of the mutated resi- 
dues were expressed i n  COS I cells, and conditioned media was 
collected 65 hours after transfection. As estimated by ELISA, 
the expression level ranged over 1 .O- 1 .5 mg/ml. As judged by 
Western blotting, wild-type and mutant recombinant factor V 
preparations all contained the 330-kDa single-chain form of 
factor V. The presence of additional bands with molecular 
masses of approximately 220-240 000 Da (doublet) and 
140 000 Da indicated that the recombinant protein was partially 
proteolyzed (Fig. 1). The 140000 band was more readily ob- 
served with the detection system (Fig. 1 B), than that used 
otherwise (Fig. 1 A). Similar bands have also been observed 
in purified plasma factor-V preparations (7, 231, in platelets 
[IS, 281 and in recombinant factor V preparations from other 
laboratories [IS]. These bands were also present in the mutant 
factor V containing Ile at position 1018, suggesting that the pro- 
teolysis was not mediated by thrombin or factor Xa. It is likely 
to be the result of an intracellular cleavage at a position slightly 
N-terminal of residue 1018. As previously shown for platelet 
factor V, the 140-kDa and 220/240-kDa bands represented the 
N-terminal and C-terminal parts of factor V, respectively [28]. 
The ELISA was eclually efficient in quantifying single-chain 
factor V as proteoly,zed factor V, which was important since the 
recombinant factor-V preparations contained partially proteo- 
lyzed products. This was assured by the essentially identical re- 
sults obtained when testing the [Gln709,Gln1545]factorV mu- 
tant with the ELISA before and after thrombin cleavage (results 
not shown). 
Proteolysis of wild-type and mutant factor V by thrombin. 
Incubation of wild-type factor V with thrombin yielded the 
heavy (105 kDa) and light (71/74 kDa) chains of factor Va, the 
150-kDa B fragment as well as bands of 220 kDa and 280 kDa, 
representing partially proteolyzed factor V (Fig. 1). The 280- 
kDa band is presumably the result of cleavage at Arg709, 
whereas the 220-kDa band was formed by cleavage at Argl018 
as shown elsewhere [7]. In our Western-blot system, the 71/74- 
kDa light chain and its typical doublet pattern were difficult to 
visualize. This may be due to bad transfer of the light chain or to 
insufficient reactivity of the factor-V serum. In order to facilitate 
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Fig.1. Western blotting of wild-type factor V and factor V mutants before and after cleavage by thrombin and factor Xa. Samples of 
conditioned medium from transfected COS cells (continaing 25-50 nM factor V) were incubated with thrombin (24 nM) or with factor Xa (factor 
V (V)/factor Xa (Xa) at 4: 1 and 1 : 1 molar ratios), phospholipids ( S O  pM) and 2.0 mM CaCl, for 10 min at 37 "C and analyzed by Western blotting 
using 5- 15 % polyacrylamide gel electrophoresis run in the presence of SDS. Samples (40 pl giving 0.3-0.7 pgllane) were reduced with dithiothrei- 
to1 and heated at 90°C for 5 min. The positions of the 330-kDa single chain (SC), 150-kDa B fragment (B), the 105-kDa heavy chain (HC), the 
72/74-kDa light chain (LC), the 48-kDa C-terminal light chain fragment (LC,) and the 30-kDa N-terminal light chain fragment (LC,) are indicated. 
Positions of molecular-mass markers are shown to the right. (A) Wild-type factor V (WT), [Gln709]factorV (QRR), [IlelOl8]factorV (RIR) and 
[Glnl545]factorV (RRQ) were detected using a polyclonal rabbit anti-human factor V serum (A299) and alkaline-phosphatase-coupled swine anti- 
rabbit serum. After development, the gel was scanned in a densitometer (Molecular Dynamics). (B) Western blotting of wild-type (WT), [Ile1018, 
Glnl545]factorV (RIQ) and [Gln709,GIn1545]factorV (QRQ). A polyclonal rabbit anti-human factor V serum (A299) was used as primary antibody 
and a fluorescein-coupled swine anti-rabbit serum as secondary antibody. The membrane was scanned in a Molecular dynamics FluorImager SI. 
(C) Western blotting of wild-type factor V(WT) and [Gln709,Ile1018]factorV (QIR). The blot was first incubated with A299, then with a fluorescein- 
labeled swine anti-rabbit serum, followed by the addition of an alkaline-phosphatase-linked anti-fluorescein serum. The blot was developed by the 
addition of the substrate Attophos, which is converted into a highly fluorescent product that adheres to the blotting membrane. The membrane was 
scanned in a Molecular dynamics FluorImager SI. (D) Western blotting of wild-type factor V (WT) and [Gln709,Ile101 8,Glnl545]factorV (QIQ) 
was performed as described in (B). 
demonstration of the light chain, an amplification system was 
used (Fig. 1 C). In some experiments, the doublet pattern of the 
light chain was observed, whereas in others the light chain ap- 
peared as a single chain. 
Mutations of the three thrombin-cleavage sites yielded the 
expected proteolytic pattern on Western blotting. Thus, as 
[Gln709]factorV was resistant to cleavage at position 709, no 
105-kDa heavy chain was formed. After proteolysis at position 
1018, the heavy chain remained connected to the 71-kDa B- 
domain activation fragment, and co-migrated with the 150-kDa 
B fragment (Fig. 1 A). The mutant [IlelOl8]factorV was resis- 
tant to thrombin cleavage at position 1018 but the heavy and the 
light chains were formed. No light chain appeared upon incuba- 
tion of [Glnl545]factorV with thrombin but cleavages at posi- 
tions 709 and 1018 yielded the heavy chain and a 220-kDa frag- 
ment which contained the light chain linked to the B region 
(Fig. 1A). 
The recombinant factor V molecules containing combina- 
tions of the three mutations also yielded the expected cleavage 
pattern (Fig. 1 B). Thrombin cleavage of [Ilel018,Gln1545]fac- 
torV yielded the heavy chain band but no light chain. The 2201 
240-kDa band present in the uncleaved recombinant was not 
cleaved further, while the 140-kDa band disappeared due to 
cleavage at Arg709. [Gln709,Glnl545]factorV was only cleaved 
at ArglOl8, as demonstrated by the appearance of 150-kDa and 
220-kDa bands. Only the light chain was released by throm- 
bin cleavage of [Gln709,Ilel018)factorV (Fig. 1 C). [Gln709, 
IlelOl8,Glnl545]factorV was resistant to thrombin cleavage and 
the Western-blot pattern remained unchanged upon incubation 
with thrombin (Fig. 1 D). 
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Fig. 2. Thrombin-activation of recombinant factor V mutants. The measured factor-Va activities before and after activation by thrombin are 
plotted for wild-type factor V (O), [IlelOl8]factorV (A), [Gln709]factorV (0). [Glnl545]factorV (+), [GIn709,11e1018]factorV (O), [Ile1018, 
Gln1545lfactorV (A), [Gln709,Gln1545]factorV(O) and [Gln709,Ile1018,Glnl545]factorV (H). In (A), the recombinant factor-V molecules were 
incubated with increasing concentrations of thrombin in buffer containing 2.0 mM CaC1, After 30 min at 37"C, the factor-Va activity was measured 
in  a prothrombinase assay. The plotted values represent means of two experiments. In (B) the different recombinant factor-V preparations (1.5 nM) 
were incubated with 3.2 nM thrombin in the presence of 2.0 mM CaCI, at 37°C. At intervals, samples were drawn and factor-Va activity measured in 
a prothrombinase assay. The plotted values represents means of three experiments performed with conditioned medium from different transfections. 
Proteolysis of wild-type and mutant factor V by factor Xa. 
The various recombinant factor V preparations were incubated 
with factor Xa at two different enzyme to substrate ratios (1 :4  
and 1 : 1). At the lower enzyme/substrate ratio, the cleavage pat- 
terns were similar to those seen when the recombinants were 
cleaved with thrombin (Fig. 1A-D) indicating that factor Xa 
cleaves at positions 709, 1018 and 1545. Thus, the heavy chain 
appeared in mutants having an arginine residue at position 709 
(wild-type factor V, [IlelOl8]factorV, [Gln1545]factorV and 
[Ile1018,Gln1545]factorV), whereas it did not appear in mutants 
containing glutamine at this position. Factor Xa is known to be 
able to cleave at position 1018 [17], which is consistent with the 
now observed resistance to cleavage at this position in mutants 
having Argl018 replaced with an Ile ([IlelOl SIfactorV, 
[IIe1028,Gln 1545]factorV, [Gln709,Ile1018]factorV and 
[Gln709,Ile1018,Glnl545]factorV). Factor Xa was found to 
cleave at Arg1545 and when this position was occupied by a 
glutamine residue, no light chain was cleaved off 
([Glnl545]factorV, [Ilel018,Gln1545]factorV, [Gln709,Gln1545]- 
factorV and [Gln709,Ile1018,Glnl545]factorV). The factor Xa 
cleavage pattern was not affected by the addition of hirudin (re- 
sults not shown), demonstrating that the cleavages were not due 
to contaminating thrombin. 
Factor Xa was also able to cleave at a position located within 
the light chain, at Arg1765. This cleavage was distinctly evident 
from incubations containing the higher factor Xa concentration 
but also noticeable in some of the incubations containing the 
lower enzyme/substrate ratio (results not shown). The smaller of 
the two fragments, LCN, was derived from the N-terminal part 
of the light chain and, therefore, not seen in the recombinant 
proteins containing glutamine at position 1545, while the 48- 
kDa C-terminal light chain fragment, LC,, was cleaved off from 
all the mutants (Fig. 1 B-D). Although not evident from the pre- 
sented pictures, in some gels, the 48-kDa fragment appeared as 
a doublet, consistent with the findings that the molecular basis 
of the light-chain doublet is located within the C-terminal region 
of the C2 domain in  the light chain [ l l ] .  Plasmin has been re- 
ported to cleave the bovine light chain into two fragments of 
M,. = 30000 and M, = 48000 [29]. To rule out the possibility 
that the light-chain cleavage was due to trace amounts of plas- 
min, the plasmin inhibitor aprotinin and the factor-Xa-inhibitor 
dansyl glutamylglycylarginine-chloromethane (Dns-Glu-Gly- 
Table 1. Factor Va activity of wild-type protein and mutant factor 
V before and after activation with thrombin or factor Xa. The curves 
presented in Figs 2 and 3 were used to estimate the EC,,,. The EC,,, 
indicates the concentration of thrombin (Ira) or factor Xa (Xa) giving 
approximately 50% dose response. 
Recombinant factor V Basal EC,,, Maximal 
factor Va factor Va 




Wild-type factor V 20 0.1 
[Gln709]factor V 5 0.3 
[Ilel018]factor V 15 1.1 
[Glnl545]factor V 12 
[Ile1018,Glnl545]factor V 8 
[Gln709,11elO1 Slfactor V 3 1.2 
[Gln709,Gln1545]factor V 3 





















Arg-CH,Cl)were used to inhibit the cleavage. No inhibition of 
light-chain cleavage by aprotinin was observed. In contrast, the 
cleavage was inhibited by Dns-GIu-Gly-Arg-CH,Cl (results not 
shown) which showed that the cleavage within the light chain 
was indeed the result of proteolysis by factor Xa. 
Identification of the factor Xa cleavage site within the light 
chain. Human plasma-derived factor V was digested with factor 
Xa ( I  : 1 molar ratio) iin the presence of phospholipids and CaCI, 
and the C-terminal-derived 46/48-kDa light-chain fragment was 
isolated by SDSPAGE and sequenced as described in Materials 
and Methods. The following amino acid sequence was obtained: 
Leu, Thr, Ser, Ser, Glu, Met, Lys, Lys, and Ser, which showed 
that factor Xa cleaved at Arg1765. 
Specific activities of mutant factor V expressed after full 
thrombin activation and relative sensitivity of different 
cleavage sites for thrombin. The ability of the recombinant 
factor V molecules to function as cofactors to factor Xa was 
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Fig. 3. Factor Xa activation of recombinant factor V mutants. The measured factor-Va activities before and after activation by factor Xa are 
plotted for wild-type factor V (0) and mutants [Ilel018]factorV (A), [Gln709]factorV (0), [Gln1545]factorV (+), [Gln709,Ile1018]factorV (O), 
[Ile1018,Glnl54S]factorV (A), [Gln709,Gln1545]factorV (0) and [GIn709,IIel018,GIn1S45]factorV (B). In (A), the recombinant factor-V mole- 
cules (1.5 nM) were incubated with increasing concentrations of factor Xa in buffer containing 2.0 mM CaCl, and 20 pM phospholipids. After 
30 min at 3 7 ° C  factor-Va activity was measured in a prothrombinase assay. The plotted values represent means of two experiments. In (B), different 
recombinant factor-V preparations (1.5 nM) were incubated with 1.5 nM factor Xa in the presence of 2.0 mM CaCl, and 20 pM phospholipids at 
37°C. At intervals, samples were drawn and the factor-Va activity measured in a prothrombinase assay. The plotted values represents means of 
three experiments performed with conditioned medium from different transfections. 
measured in a prothrombinase assay before and after incubation 
of 1.5 nM recombinant protein with increasing concentrations of 
thrombin (0-6.4 nM; Fig. 2A). The concentration causing 50% 
effect for wild-type factor V was 0.1 nM thrombin (Table I) ,  
whereas tenfold more thrombin (concentration causing 50% ef- 
fect = 1.1 nM) was required for [IlelOl8]factor V to express the 
same specific activity. This is in agreement with the suggestion 
made by Marquette et al. [25] that cleavage at position 1018 
results in a conformational change at the cleavage site at position 
1545, which makes it more susceptible to thrombin. The concen- 
tration causing 50% effect for [Gln709]factorV (0.3 nM) was 
threefold higher than that of the wild-type, indicating that cleav- 
age at Arg709 may have a similar effect. When both positions 
709 and 101 8 were mutated ([Gln709,Ile1018]factorV), the con- 
centration causing 50% effect was 1.2 nM, i.e. Arg1545 was less 
sensitive to thrombin digestion than when Arg709 and ArglOl8 
were individually mutated. The concentration causing 50 % ef- 
fect could not be estimated for the other mutants tested, but the 
activity of [Gln709,Gln1545]factorV increased slightly, whereas 
the activity of [Gln709,Ile1018,Glnl545]factorV did not change 
upon thrombin activation (Fig. 2A). 
Wild-type factor V was rapidly activated by thrombin and 
reached its maximum activity (1 00 U/mg) after 5 - 10 min incu- 
bation. Activation of [IlelOl8]factorV was slower and the peak 
activity (95 U/mg) occurred after 20 min. [Gln709]factorV was 
maximally activated after 10-20 min, while [Gln709,Ile1018]- 
factorV had to be activated for 20-30 min with thrombin in 
order to reach its peak activation (Fig. 2B). 
Comparison of the specific activities of the fully activated 
recombinant factor-V mutants demonstrated the importance of 
cleavage at both positions 709 and 1545 for expression of full 
factor-Va activity (Fig. 2B, Table 1). When either of these two 
sites were mutated, as in [Gln709]factorV and [Gln1545]factorV, 
the specific activities were less than 30% of those expressed by 
wild-type factor Va or fully activated [Ilel 01 8lfactorV. Mutants 
having arginine at position 709 all expressed higher basal activi- 
ties as compared to those having glutamine at this position. The 
cleavage at position 709 is very sensitive to both thrombin and 
to factor Xa; this is possibly due to cleavage at Arg709 during 
the prothrombinase assay. 
Specific activities of mutant factor V expressed after full 
factor-Xa activation and relative sensitivity of different 
cleavage sites for factor Xa. Factor V recombinants (1.5 nM) 
were incubated with increasing concentrations of factor Xa (0- 
1.5 nM) in the presence of phospholipids (20 pM) and CaCl, 
(2.0 mM) for 30 min at 37°C and the factor-Va activity mea- 
sured (Fig. 3A and Table l). The specific activity of factor Xa- 
cleaved wild-type factor V (99 U/mg) was similar to that ob- 
served after thrombin activation (100 U/mg). Cleavages at both 
positions 709 and 1545 were found to be required for full activa- 
tion of factor V by factor Xa, whereas the cleavage at position 
1018 was of less significance. This conclusion was based on the 
following observations. (A) The very low concentration causing 
50% effect for wild-type factor V (0.05 nM) as compared to that 
of [Gln709]factorV (0.3 nM) demonstrated the site at Arg709 to 
be very sensitive to cleavage by factor Xa and that this cleavage 
is important for further proteolysis of the factor-V molecule. (B) 
The low specific activity of fully activated [Glnl545]factorV 
demonstrated the cleavage at position 1545 is essential for ex- 
pression of full activity even though it was less sensitive to 
factor Xa than that at position 709 (as demostrated by a concen- 
tration causing 50% effect of 0.3 nM for [GIn709,Ile1018]fac- 
torV). (C) The sensitivity of [IlelOl8]factorV (concentration 
causing 50% effect of 0.15 nM) was only slightly lower than 
that of wild-type factor V (concentration causing 50% effect of 
0.05 nM), suggesting the cleavage site at position 1018 is of 
relatively minor importance. 
Several of the mutants, e.g. [Gln709]factorV, [Ile1018, 
Gln1545lfactorV, [Gln709,Gln1545]factorV, [Gln709,Ile1018]- 
factorV and [Gln709,Ile1018,Gln1545]factorV, expressed 
higher specific activity after incubation with factor Xa than after 
thrombin incubation (Fig. 3B, Table l), e.g. the activity of 
[Gln709,Gln1545]factorV increased from 3 U/mg before activa- 
tion to 19 U/mg after 20 min activation. The activity after throm- 
bin activation of this mutant was only 5 U/mg. Likewise, upon 
incubation with factor Xa, the activity of [Gln709,Ile1018, 
Glnl545lfactorV increased to 14 U/mg, whereas no increased 
activity was observed after incubation with thrombin. The in- 
creased activity observed after factor-Xa activation was presum- 
ably the result of the factor Xa-mediated cleavage at Arg1765. 
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Fig. 4. Schematic model of wild-type factor V (WT) and factor V mutants [Gln709]factorV (QRR), [IlelOlS]factorV (RIR), [Glnl545]factorV 
(RRQ), [Ile1018,Gln1545]factorV (RIQ), [Gln709,GlnIS45]factorV (QRQ), [Gln709,Ile1018]factorV (QIR) and [Gln709,Ilel018,Glnl545]- 
factorV (QIQ) after thrombin and factor Xa cleavage. (A) Single-chain factor V (Mv 330) is comprised of multiple regions which are arranged 
in the order AI-A2-B-A3-Cl-C2. Cleavage at Arg709, ArglOl8 and Arg1545 leads to a molecuiar rearrangement and the formation of factor Va, 
which functions as cofactor to factor Xa. Factor Va is formed by the heavy chain (HC) and the light chain (LC) which are held together by non- 
covalent calcium-dependent bonds. The heavy chain is composed of A1 and A2 modules, whereas the light chain contains A3, C1 and C2 modules. 
(B) Schematic representation of the active factor-Va molecules which are formed upon incubation with thrombin or FXa. Asterisks denote an 
interaction between the fragments. Shaded boxes represent the heavy and light chains. 
The factor-Va activity expressed after cleavage of [Gln709, 
Ile1018,Glnl54S]factorV with factor Xa was labile (Fig. 3). 
Maximum factor-Va activity for this mutant was expressed after 
10 min incubation with factor Xa, then the activity declined dur- 
ing the following 20 min. This decline in activity explains why 
(Fig. 3 A) increasing concentrations of factor Xa did not appear 
to lead to increased factor-% activity as the activity in this ex- 
periment was measured after 30-min incubation. That incubation 
of [Gln709,11e1018,Glnl545]factorV with factor Xa indeed led 
to increased factor-Va activity was further demonstrated in an 
experiment in which [Gln709,Ile1018,Glnl54S]factorV (1 .S nM 
final concentration) was mixed with factor Xa (1.5 nM) and 
phospholipid (20 pM) in Tris/NaCI/BSA with 2.0 mM CaCl,. 
Prothrombin (1.4 pM) was either added immediately or after 
10 min incubation at 37"C, and the rate of thrombin generation 
was followed during 5 min. When prothrombin was added im- 
mediately, no thrombin generation was observed. In contrast, 
20 U/ml thrombin was formed during the first minute in the in- 
cubated factor-Xa/~Gln709,11e1018,Gln1545]factorV mixture. 
This was most likely due to the factor-Xa-mediated cleavage at 
Arg1765 by factor Xa. 
The relative rates by which the four factor-Xa-cleavage sites 
were cleaved were estimated from the time course of the activa- 
tion reactions (Fig. 3 B, Table 1). It is noteworthy that the activi- 
ties of wild-type factor V, [1le1018]factorV,[G1n709]factorV and 
[Gln709,Ile1018]factorV, which all were cleaved at Arg1.545 and 
within the light chain, continued to increase throughout the 
30 min of incubation with factor Xa, suggesting the Arg1.545 
cleavage to be relatively slow. In contrast, the increase in  activ- 
ity of [Glnl54SlfactorV and [IlelOl8,Glnl54S]factorV observed 
after addition of factor Xa was very fast and maximum activity 
was already expressed after 5 min. Thereafter, the activities of 
these preparations slowly declined. The similar activation pat- 
terns of [IleIOl8,GlnlS4S]factorV and [GlnlS45]factorV sup- 
port the notion that cleavage at position 1018 is of minor impor- 
tance for factor Xa activation and that the site at position 709 is 
efficiently and very rapidly cleaved by factor Xa. 
DISCUSSION 
Activation of human and bovine plasma-derived factor V by 
thrombin has been extensively studied by several investigators 
[S-7]. Keller and coworkers [IS] used in vitro mutagenesis and 
expression of mutated recombinant factor V to elucidate which 
of the thrombin cleavage sites were necessary for the activation 
of human factor V by thrombin. From their work they concluded 
that cleavage at Arg'709 resulted in little increase in cofactor 
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activity, but that this cleavage was important for rapid thrombin 
cleavage at Arg1.545 and maximal activation by thrombin. They 
concluded that cleavage of Arg1545 was most important for ex- 
pression of full factor-Va activity. Our results obtained on the 
thrombin-mediated activation of factor V confirm those of Kel- 
ler et al. [I51 and further show the importance of the cleavage 
at Arg709. This cleavage is very rapid, which presumably ex- 
plains the high basal factor-Va activity expressed by recombi- 
nant factor V mutants having Arg at position 709, and it is 
needed for expression of maximal factor-Va activity. Cleavage 
at ArglOl8 by thrombin or factor Xa did not lead to increased 
factor-Va activity, suggesting that cleavage of this site may have 
another function. Marquette et al. [25] reported that cleavage at 
position 101 8 facilitated further cleavage at position 1545 and 
our results were in agreement with this conclusion. We found 
the cleavage site at position 709 to have a similar function. In 
contrast, we obtained no indication to suggest that the cleavage 
site at position 1545 or that mutation at this site affects the 
cleavages at positions 709 or 1018. This also agrees with obser- 
vations made in previous time-course studies demonstrating the 
individual sensitivities of the various sites for thrombin. In these 
experiments, it was shown that the site at position 1545 was less 
readily cleaved than the other two sites by thrombin and that the 
cleavage at position 1545 is the last site to be cleaved during 
thrombin activation [7]. 
It was noteworthy that mutants with arginine at position 
1545 ([Gln709]factorV and [Gln709,11el018]factorV) did not 
give full activity after activation with thrombin or factor Xa. 
This is surprising as these recombinant molecules, after activa- 
tion, yield a form of factor V similar to factor V cleaved by the 
RVV factor-V activator, which has been reported to have the 
same activity as thrombin-activated factor V. It is possible that 
mutation at positions 709 and 1018 might cause secondary 
changes in the conformation of factor V such that the cleavage 
at position 1545 is significantly influenced. As a result, thrombin 
would be less efficient in cleaving this site in mutant factor V 
compared to wild-type factor V. For this reason, we also tried to 
activate the mutant factor V with a combination of thrombin 
and the RVV factor-V activator. However, the activities of the 
[Gln709]factorV and [Gln709,Ile1018]factorV mutants were 
found not to increase further after combined activation with 
thrombin and RVV factor-V activator (results not shown), which 
indicate that the low activities were not related to partial cleav- 
age at position 1545, but that they were inherent properties of 
the two mutants. Moreover, on Western-blot analysis, we found 
that the mutant factor-V species were fully cleaved after throm- 
bin digestion. Possibly, the low specific activity of fully acti- 
vated [Gln709]factorV and [GIn709,Ilel018]factorV is caused 
by secondary conformational changes in factor V induced by 
the mutation. Alternatively, the specific activity of the wild-type 
activated by RVV factor V activator may not represent the activ- 
ity of factor V which is only cleaved at position 1545, but rather 
factor V which is cleaved at both positions 709 and 1545, be- 
cause the site at position 709 probably is rapidly cleaved by 
factor Xa during the prothrombinase assay which is used to 
quantify factor-Va activity. This could also explain the observed 
higher basal activities expressed by mutants having arginine at 
position 709 as compared to those having glutamine at this posi- 
tion. 
Moncovic et al. [I71 reported that factor Xa did not cleave 
plasma-derived factor V at position 1545. Our results demon- 
strate that factor Xa is able to cleave factor V at the same three 
sites as thrombin, i.e. at positions 709, 1018 and 1545. The most 
striking difference between our results and those on record is 
that we found the cleavage at Arg1545 to be crucially important 
for expression of full factor-% activity after factor Xa cleavage, 
whereas Moncovic and Tracy [17, 181 reported cleavage at 
Argl018 to be sufficient. In our hands, cleavage at position 1545 
was not only observed for recombinant factor V but also for 
factor V purified from human plasma, which rules out the possi- 
bility that the specific factor-Xa cleavage pattern now observed 
was only valid for recombinant factor V. In our experimental 
system, cleavage at Argl018 by factor Xa did not result in 
increased factor-Va activity, which was most clearly demon- 
strated by the observation that [Gln709,Gln1545]factorV and 
[Gln709,Ile1018,Glnl545]factorV after incubation with factor 
Xa expressed similar specific activities. It is likely that the low 
biological activity of cleaved [Gln709,Glnl545]factorV is due 
to resistance to cleavage at the mutated positions (positions 709 
and 1545) even though the possibility that the loss of biological 
activity was due to secondary-structural changes caused by the 
mutations cannot be completely ruled out. 
Factor Xa was also found to cleave human recombinant and 
plasma-derived factor V at Arg1765, a site located within the 
A3 domain of the light chain. The cleavage yielded two frag- 
ments of 30 kDa and 48 kDa, the latter being derived from the 
C-terminal half of the light chain, In this context, it is note- 
worthy that bovine factor V [I91 and bovine factor Va [30] have 
been shown to be cleaved by factor Xa at a site located within 
the light chain between Arg1753 and Ala 1754 [31]. Moreover, 
factor Xa cleaves factor VIII at the same sites as thrombin and, 
in addition, at a site within the light chain, at Arg1721 [32]. 
Recently, it was demonstrated that this latter factor Xa cleavage 
was associated with factor VIII activation [33]. As judged from 
our studies, human factor V and factor VIII are similar in the 
respect that both molecules can be activated by factor Xa cleav- 
age in the A3 domain. 
The different molecular structures of the factor Va species 
formed upon thrombin or factor Xa cleavage of the recombinant 
factor V mutants (Fig. 4) may explain the different specific 
activities observed. Factor Va formed after thrombin cleavage of 
wild-type factor V and [IlelO18]factorV are identical and ex- 
press similar specific activities. The same holds true for the 
factor-Xa-activated forms. It is known that the heavy chain of 
factor Va interacts with prothrombin [12] and that both the light 
chain and the heavy chain bind to factor Xa [13, 341. The lower 
specific activities expressed of the mutants which were not 
cleaved at either positions 709 or 1545 were probably caused by 
the B-region fragments which remained attached to either the 
heavy or the light chains. It remains to be elucidated whether 
these attached fragments affect binding of factor Xa, the factor 
Xa catalytic activity or the interaction of prothrombin with the 
respective prothrombinase complex. 
Our study provides new information on the activation of 
factor V by factor Xa and an idea about the specific activities 
of the fully activated factor-V mutants. These latter results are 
of biological interest because some of the activated factor-V mu- 
tants correspond to activation intermediates which are formed 
during physiological activation of factor V. Thus, fully activated 
[IlelOI 8, Glnl545]factorV and [Glnl545]factorV correlates to 
such activation intermediates, i.e. factor V cleaved at position 
709 or at position 709 plus position 1018, respectively. The 
higher activity of [IlelO18,Glnl545]factorV as compared to 
[GIn709,Ile1018,GlnI545]factorV suggests that the rapid initial 
cleavage at position 709 is associated with increased factor-V 
activity which may be crucial for early positive feed-back ampli- 
fication of the coagulation system. 
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